Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin

Paul McNamee, Eddy van Doorslaer, Rob Segaar

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)


Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.

Original languageEnglish
Pages (from-to)490-504
Number of pages15
JournalInternational Journal of Technology Assessment in Health Care
Issue number4
Publication statusPublished - 1993

Bibliographical note

Funding Information:
The authors acknowledge the financial support of the Dutch Health Council. We also thank Anton van Boxtel of the Health Council for his help in providing us with data from a survey conducted by Dialyse Groep Nederland.

Cite this